If bone scan, CT, and PSMA PET reveal multiple metastases, is radical prostatectomy considered a first‑line therapy?

Radical Prostatectomy is NOT First-Line Therapy for Multiple Metastases

In the presence of multiple metastases detected by bone scan, CT, and PSMA PET, radical prostatectomy is contraindicated as first-line therapy; systemic treatment with ADT plus intensification (docetaxel and/or novel hormonal agents like abiraterone, apalutamide, enzalutamide, or darolutamide) represents the standard of care 1, 2.

Why Surgery is Not Appropriate

When imaging reveals multiple metastases, the disease is classified as metastatic castration-sensitive prostate cancer (mCSPC). At this stage:

• The cancer has spread beyond the prostate to distant sites (bones, lymph nodes, visceral organs)
• Local therapy alone (surgery or radiation to the prostate) cannot address systemic disease burden
• Survival benefit comes from systemic therapy, not from removing the primary tumor

Standard First-Line Treatment for Multiple Metastases

For Fit Patients with De Novo mCSPC

The evidence-based approach prioritizes triplet therapy 2:

ADT + Docetaxel + Novel Hormonal Agent (abiraterone or darolutamide) is recommended, particularly for patients with:

• Multiple bone metastases (>3)
• Visceral metastases
• High-volume disease

Alternative doublet therapy 2:

• ADT + abiraterone + prednisone
• ADT + apalutamide
• ADT + enzalutamide
• ADT + darolutamide

These combinations have demonstrated superior overall survival and progression-free survival compared to ADT alone, with ESMO-MCBS scores of 4 (indicating substantial clinical benefit).

For Vulnerable/Unfit Patients

ADT alone should only be used in patients who cannot tolerate treatment intensification 2.

Role of Local Therapy in Metastatic Disease

When Local Therapy May Be Considered

Local therapy (radiation or surgery) to the prostate or metastatic sites is only appropriate in highly selected scenarios:

1. Low-Volume Disease with Radiation to Primary Tumor 1:

• Defined as ≤3 bone metastases (none in axial skeleton beyond vertebral bodies/pelvis) AND no visceral metastases
• ADT + abiraterone + radiation to the prostate improved radiographic PFS (7.5 vs 4.4 years)
• This is radiation, not surgery

2. Oligometastatic Disease (≤5 metastases by conventional imaging or ≤10 by PSMA-PET) 1:

• Metastasis-directed therapy (MDT) with radiation to all metastatic sites
• Improved ADT-free survival and PFS in randomized trials (ORIOLE, STOMP, EXTEND)
• Goal is to treat all metastatic sites, not just the prostate
• This approach is investigational and requires careful patient selection

Critical Distinction: Multiple vs. Oligometastatic

Your question specifies multiple metastases. This terminology suggests:

• High metastatic burden (not oligometastatic)
• Widespread disease requiring systemic control
• Not a candidate for MDT or cytoreductive surgery

The upper limit for considering local therapy is generally ≤5 metastases by conventional imaging or ≤10 by PSMA-PET 1. Beyond this threshold, systemic therapy alone is appropriate.

PSMA PET Impact on Staging

PSMA PET/CT has superior sensitivity compared to conventional imaging 3, 4, 5:

• Changes clinical management in 22.6% of patients during primary staging 3
• Detects more skeletal metastases than bone scan (10.3% vs 7.3%) 5
• Identifies oligometastatic disease that may be amenable to MDT 6

However, more sensitive detection of metastases reinforces the need for systemic therapy, not surgery, as the primary treatment modality.

Common Pitfalls to Avoid

1. Do not perform radical prostatectomy for cytoreduction in metastatic disease - no survival benefit and significant morbidity
2. Do not confuse oligometastatic disease (≤5 lesions) with multiple metastases - treatment paradigms differ
3. Do not delay systemic therapy - early intensification with ADT + docetaxel + novel hormonal agent improves survival in high-volume disease
4. Do not use ADT monotherapy unless the patient is truly unfit for intensification

Treatment Algorithm for Multiple Metastases

1. Confirm metastatic disease with PSMA PET (if available) or conventional imaging
2. Assess fitness for chemotherapy and treatment intensification
3. Initiate systemic therapy:
   • Fit patients: ADT + docetaxel + abiraterone/darolutamide
   • Alternative: ADT + novel hormonal agent (abiraterone, apalutamide, enzalutamide, darolutamide)
   • Unfit patients: ADT alone
4. Consider palliative radiation for symptomatic bone metastases or spinal cord compression
5. Reserve surgery for complications (urinary obstruction, bleeding) only

Radical prostatectomy has no role in the curative or palliative management of prostate cancer with multiple metastases 1, 2.